Rare Neurology News

Advertisement

Spotlight On

Myasthenia Gravis

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles

Prevalence

1-9 / 1,000,000

3,310-29,790

US Estimated

5,135-46,215

Europe Estimated

Age of Onset

ICD-10

G70.0

Inheritance

Autosomal dominant

Autosomal recessive

Mitochondrial/Multigenic

X-linked dominant

X-linked recessive

5 Facts you should know

FACT

1

The clinical hallmark of MG is the presence of fluctuating fatigable muscle weakness that worsens with activity and improves on rest

FACT

2

It most commonly impacts young adult females (under 40) and older males (over 60), but it can occur at any age, including childhood

 

FACT

3

MG is caused by an antibody-mediated blockade of neuromuscular transmission, resulting in skeletal muscle weakness and rapid muscle fatigue

FACT

4

The ocular and bulbar muscles are affected most commonly and most severely, but most patients also develop some degree of fluctuating generalized weakness

 

FACT

5

MG is idiopathic in most patients

 

Myasthenia Gravis is also known as...

Myasthenia Gravis is also known as:

 

  • MG
  • Grave's Disease
  • Muscle Weakness Disease
  • Autoimmune Myasthenia
     

What’s your Rare IQ?

Which famous actor suffered from Myasthenia Gravis?

Common signs & symptoms

Abnormality of the thymus

Acetylcholine receptor antibody positivity

Bulbar palsy

Diplopia

Dysarthria

Dysphagia

Dyspnea

Muscle specific kinase antibody positivity

Current treatments

The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. Learn more orphan products.

[table “” not found /]

Top Clinical Trials

Top Treatments in Research